Peptide synthesis, whether solid-phase chemical synthesis or recombinant production, can produce byproducts, truncated sequences, or incompletely formed molecules alongside the intended target peptide. Without independent verification, there is no way to know what percentage of a given vial or batch is actually the correctly synthesized compound versus impurities.
This matters more in the unregulated research-chemical space than in regulated pharmaceutical manufacturing, because there is no government inspection regime requiring or verifying quality documentation for research chemicals the way there is for approved drugs.
High-Performance Liquid Chromatography (HPLC) is the standard analytical method the research-peptide field uses to measure purity. A sample is passed through a column under pressure, and different molecules separate and elute at different times based on their chemical properties, producing a chromatogram. Analysts calculate what percentage of the total sample corresponds to the correctly formed target molecule, expressed as a purity percentage — commonly in the high-90s range for a well-manufactured batch.
HPLC is typically paired with mass spectrometry, which confirms molecular weight and identity — verifying that the synthesized molecule actually matches the intended peptide sequence, rather than a structurally similar but incorrect variant that might otherwise pass a purity check without confirming true identity.
A Certificate of Analysis (COA) compiles these test results — typically HPLC purity and mass-spectrometry identity confirmation — for one specific production lot. Because purity and quality can vary meaningfully between batches even from the same supplier, the research-chemical field generally advises requesting lot-specific COAs rather than relying on generic marketing claims that may not correspond to the actual vial in hand.
This is standard practice across legitimate research-peptide suppliers, and it is the documentation researchers look for when evaluating whether a given source is reliable.
For compounds like IGF-1 LR3 that circulate exclusively as unregulated research chemicals — with no government body inspecting manufacturers or verifying labels — independent quality verification becomes the only real safeguard against mislabeled, underdosed, or counterfeit products. General commentary on this market consistently flags counterfeit and quality-control risk as a defining feature of the unregulated space.
This article explains the general concepts researchers use to evaluate quality across the research-peptide category broadly; it does not provide or imply any product-specific purity data.
REVIVE LAB UAE documents its actual catalog products with lot-specific Certificates of Analysis, reflecting the quality-verification standard described in this article. IGF-1 LR3, however, is not part of that catalog, so no IGF-1 LR3-specific COA, purity data, or product specification exists on this site or is implied by this content.
This article is educational context on how quality control works across the research-peptide field generally, applicable to anyone evaluating any research-chemical source.